Home › Compare › NFONF vs ABBV
NFONF yields 9.26% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 2
Combined, NFONF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NFONF + ABBV for your $10,000?
NFON AG provides cloud-based telecommunication services to business customers in Germany, Austria, Italy, the United Kingdom, Spain, France, and Portugal. It offers Cloudya and centrexx products for customers with the required brokerage service from the cloud in its data centers through the cloud private branch exchange; and telephone conference services. The company also provides various solutions, such as Nconnect voice for IP communications; Nconnect data, which allows Internet access; Ncontactcenter, a cloud contact centre solution, that facilitates customer support for various channels, agents, and locations; Nhospitality, which integrates cloud telephony into property management systems for hotel industry; Neorecording that allows companies to record conversations and retain them in a tamper-proof and encrypted environment; Nmonitoring Queues to monitor and track internal work performance; and Noperatorpanel, which provides a professional voice reception panel for customers to receive incoming calls and forward certain calls to their intended recipients. In addition, its product portfolio includes unified communications and collaboration, such as Meet and Share; integration for Microsoft Teams; and business applications comprising CRM Connect, as well as sells devices, such as telephones, soft clients for PCs and smartphones, and related software. The company has an agreement with Meetecho. NFON AG was founded in 2007 and is headquartered in Munich, Germany.
Full NFONF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.